Entrada Therapeutics TRDA Cash Flow Statement (2020-2026)

NASDAQ TRDA
$4.65 -0.34 (-6.81%)
At close: Oct 21, 2026 · 4:00 PM EDT
Reported Financials

Entrada Therapeutics Quarterly Cash Flow Statement

Periods 24 quarters
Latest Jun 2026

Entrada Therapeutics reported cash from operations of -$32.46M and free cash flow of -$32.47M for the quarter ended Jun 2026, down 10.1% year over year. This cash flow statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-14.43M-18.49M-21.67M-23.18M-25.14M-24.63M-6.67M-25.93M35.46M-9.54M23.50M55.03M-14.03M1.13M-17.35M-43.10M-44.13M-39.16M-39.72M-42.76M
Depreciation and DepletionDep. & Depletion
0.30M0.32M0.40M0.50M0.50M0.50M0.54M0.70M0.80M0.74M0.93M0.90M0.90M1.00M0.95M1.10M1.20M0.89M0.81M0.80M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.30M0.32M0.40M0.50M0.50M0.50M0.54M0.70M0.80M0.74M0.93M0.90M0.90M1.00M0.95M1.10M1.20M0.89M0.81M0.80M
Share-based CompensationStock Comp.
0.58M1.46M1.79M2.51M2.71M2.88M2.76M3.12M3.40M3.84M3.73M4.62M4.86M4.70M5.09M5.05M5.12M4.36M4.74M5.15M
Gains from Sales and DivestituresGains Divest
-0.15M0.08M0.00M0.00M
Change in Working Capital
Change in Account PayablesChange Payables
0.08M-1.03M2.06M1.54M-2.91M4.59M0.53M-4.38M-1.37M2.41M-0.66M-0.89M-0.31M2.85M-1.91M-0.32M1.31M-0.88M0.64M0.82M
Change in Accured ExpensesChange Accured Exp.
2.07M1.82M-1.53M0.73M6.90M-4.34M4.11M-5.05M2.80M1.96M-2.52M1.62M3.04M-0.43M-5.46M4.31M3.74M2.15M-5.95M1.27M
Change in TaxesChange Taxes
7.36M-7.36M4.02M1.83M-1.74M-1.86M-1.58M0.14M-0.80M0.62M-0.62M
Change in Other Operating AssetsOther Assets Change
2.60M4.69M0.65M-1.73M7.57M4.22M7.26M-11.97M14.24M-12.70M66.40M-71.56M-6.41M0.94M-2.11M-8.33M-7.31M-3.29M0.40M-3.96M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.22M0.06M-1.53M-1.94M-1.96M-2.01M209.63M-21.22M-42.17M-18.13M16.10M-89.01M-20.10M-35.82M-20.72M-3.02M-2.76M-1.59M-1.27M-1.29M
Other Working Capital ChangesOther WC Changes
-2.82M-4.64M-2.18M-0.22M-9.53M-6.23M202.37M-9.25M-56.41M-5.43M-50.30M-17.46M-13.68M-36.76M-18.62M5.30M4.55M1.70M-1.67M2.67M
Cash from OperationsCash from Ops.
-14.08M-20.54M-20.99M-18.01M-27.48M-27.30M203.40M-35.09M-24.49M-4.01M-25.52M39.83M-24.27M-31.61M-38.51M-29.49M-28.31M-32.20M-41.70M-32.46M
Investing Activities
Capital ExpendituresCapex
0.81M1.32M0.59M0.78M0.81M0.71M1.67M1.52M1.45M0.98M0.84M1.05M0.64M0.64M1.14M0.28M-0.17M-0.21M0.04M0.01M
Change in Property, Plant and EquipmentChange in PP&E
-0.81M-1.32M-0.59M-0.78M-0.81M-0.71M-1.67M-1.52M-1.45M-0.98M-0.84M-1.05M-0.64M-0.64M-1.14M-0.28M0.17M0.21M-0.04M-0.01M
Purchase of InvestmentsInvestments Purchased
182.65M39.32M101.78M140.12M76.79M88.52M96.94M110.69M165.59M64.50M80.02M16.55M26.57M18.47M11.83M3.93M
Sale and Maturity of InvestmentsInvestments Sold
1.71M25.00M30.00M19.50M63.00M28.39M74.50M108.54M123.92M87.36M83.31M118.50M85.95M50.63M75.50M47.39M38.86M58.89M
Cash from Investing ActivitiesCash from Investing
-0.81M-1.32M-181.53M24.23M-10.13M18.79M-40.44M-113.26M-3.74M19.04M26.15M-24.38M-82.93M53.37M4.78M33.80M49.11M29.12M26.99M54.95M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
0.11M190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Net Shares Issued and RepurchasedNet Shares Issued
0.11M190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
0.11M190.76M0.05M0.01M0.06M0.36M19.54M-18.96M0.37M0.69M0.21M101.37M-0.01M-98.21M0.35M0.34M0.01M0.19M0.10M0.35M
Cash from Financing ActivitiesCash from Financing
0.11M190.76M0.05M0.01M0.06M0.36M19.54M0.44M0.37M0.69M0.21M101.37M-0.01M1.40M0.35M0.34M0.01M0.19M0.10M0.35M
Additional items
Change in Cash
-14.78M168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.65M20.80M-2.89M-14.61M22.84M
Ending Cash Balance
122.17M291.06M88.59M94.82M57.26M49.11M231.60M83.69M55.83M71.55M72.39M189.20M82.00M105.16M71.79M76.43M97.24M94.34M79.74M102.57M
Free Cash FlowFCF
-14.88M-21.86M-21.59M-18.78M-28.29M-28.01M201.73M-36.61M-25.94M-4.99M-26.36M38.79M-24.91M-32.24M-39.65M-29.76M-28.14M-32.00M-41.74M-32.47M
Net Cash FlowNCF
-14.78M168.89M-202.47M6.23M-37.56M-8.15M182.49M-147.91M-27.86M15.72M0.83M116.82M-107.20M23.16M-33.37M4.65M20.80M-2.89M-14.61M22.84M

Entrada Therapeutics Cash Flow Statement API

Pull Entrada Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=TRDA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY